Loading...
XSWX
LONN
Market cap50bUSD
Aug 28, Last price  
583.80CHF
Name

Lonza Group AG

Chart & performance

D1W1MN
XSWX:LONN chart
P/E
42.97
P/S
6.24
EPS
13.59
Div yield, %
0.69%
Shrs. gr., 5y
-1.24%
Rev. gr., 5y
7.70%
Revenues
Net income
CFO
Dividend
May 12, 20265 CHF/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules segment design, development, and manufacturing, with the ability to offer integrated drug substances to drug product solutions, including particle engineering and drug product packaging. The Cell and Gene segment develops, de-risk, commercializes, and scales their emerging therapies through its three business areas Cell and Gene Technologies, Bioscience, and Personalized Medicine. The Capsule and Health Ingredients segment provides innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies. The Corporate segment refers to finance and accounting, legal, communication, information technology, and human resources functions. The company was founded on October 27, 1897 and is headquartered in Basel, Switzerland.
IPO date
Apr 03, 2002
Employees
17,896
Domiciled in
CH
Incorporated in
CH

Valuation

No data to show